Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Northwest Clinical Research Center, Bellevue, WA, USA; 2Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA; 3Department of Psychiatry, University of Connecticut, Hartford, CT, USA; 4Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA
Список исп. литературыСкрыть список 1. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch GenPsychiatry 2000;57:311-7. 2. Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002;5:193-7. 3. Walsh BT, Seidman SN, Sysko R et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2001;287:1840-7. 4. Khan A, Detke M, Khan S et al. Placebo response and antidepressant clinical trial outcome. J NervMent Dis 2003;191:211-8. 5. Rief W, Nestoriuc Y, Weiss S et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009;118:1-8. 6. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012;37:851-64. 7. Weimer K, Colloca L, Enck P. Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2015;2:246-57. 8. Mancini M, Wade AG, Perugi G et al. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants. J Psychiatr Res 2014;51:21-9. 9. Khin NA, Chen Y, Yang Y et al. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of New Drug Applications. J Clin Psychiatry2011;72:464-72. 10. Furukawa TA, Cipriani A, Atkinson LZ et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomized controlled studies. Lancet Psychiatry 2016;3:1059-66. 11. Enck P. Placebo response in depression: is it rising? Lancet Psychiatry2016;3:1005-6. 12. Khan A, Kolts RL, Thase ME et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004;161:2045-9. 13. Papakostas GI, Ostergaard SD, Iovieno N. The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015;76:456-66. 14. Khan A, Leventhal RM, Khan SR et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J ClinPsychopharmacol 2002;22:40-5. 15. Khan A, Brodhead AE, Kolts RL et al. Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials. J PsychiatrRes 2005;29:145-50. 16. Khan A, Schwartz K, Kolts RL et al. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry2007;62:65-71. 17. Khan A, Khan SR, Walens G et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration Summary Basis of Approval reports. Neuropsychopharmacology2003;28:552-7. 18. Khan A, Khan SR, Leventhal RM et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database. Int J Neuropsychopharmacol2001;4:113-8. 19. Demitrack MA, Faries D, Herrera JM et al. The problem of measurement error in multisite clinical trials.Psychopharmacol Bull 1998;34:19-24. 20. Kobak K, Thase ME. Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J ClinPsychopharmacol2007;27:1-5. 21. Kobak KA, Feiger AD, Lipsitz JD. Interview quality and signal detection in clinical trials. Am J Psychiatry 2005;162:628. 22. Khan A, Faucett J, Brown WA. Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped, and appraised rater interviews compared to traditional rating interviews. J Psychiatr Res 2014;51:88-92. 23. Khan A, Faucett J, Brown WA. Magnitude of change with antidepressants and placebo in antidepressant clinical trials using structured, taped and appraised rater interview (SIGMA-RAPS) compared to trials using traditional semi-structured interviews. Psychopharmacology2014;231:4301-7. 24. Stein DJ, Baldwin DS, Dolberg OT et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebocontrolledstudies of escitalopram. J Clin Psychiatry 2006;67:1741-6. 25. Kirsch K, Deacon BJ, Huedo-Medina TB et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:e45. 26. Fournier JC, DeRubeis RJ, Hollon SD. Antidepressant drug effects depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53. 27. Naudet F, Millet B, Charlier P et al. Which placebo to cure depression? Athought-provoking network meta-analysis. BMC Med 2013;11:230. 28. Moncrieff J. Antidepressants: misnamed and misrepresented. World Psychiatry 2015;14:302-3. 29. Fountoulakis KN, M€oller H. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011;14:405-12. 30. Cipriani A, Geddes JR. Placebo for depression: we need to improve the quality of scientific information but also reject too simplistic approaches or ideological nihilism. BMC Med 2014;12:105. 31. Montgomery SA. Antidepressant or antidepressant plus placebo effect? World Psychiatry 2015;14:303-4. 32. Kasper S, Dold M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry 2015;14:304-6. 33. Khan A, Brown WA. Antidepressants vs. placebo in major depression: an overview. World Psychiatry 2015;14:294-300. 34. Moore TJ, Mattison DR. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern Med 2017;177:274-5. 35. Sinyor M, Levitt AJ, Cheung AH et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analysis. J Clin Psychiatry 2010;71:270-9. 36. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. EurNeuropsychopharmacol 2009;19:34-40. 37. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013;170:723-33. 38. Food and Drug Administration. www.accessdata.fda.gov. 39. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60. 40. Lee K, Bacchetti P, Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008;5:1348-56. 41. Gibertini M, Nations K, Whitaker J. Obtained effect size as function of sample size in approved antidepressants: a real-world illustration in support of better trial design. IntClinPsychopharmacol 2012;27:100-6. 42. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med2008;358:252-60. 43. Mahableshwarkar A, Jacobsen P, Serenko M et al. A randomized, doubleblind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. J Clin Psychiatry 2015;76:583-91. 44. Liu KS, Snavely DB, Ball WA et al. Is bigger better for depression trials? J Psychiatr Res 2008;42:622-30.